Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilnidipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 8/20 | 1.00 |
| ▸ | CACNA1F known ✓ | O60840 | 7/20 | 0.69 |
| ▸ | CACNA1D known ✓ | Q01668 | 7/20 | 0.69 |
| ▸ | CACNA1S known ✓ | Q13698 | 7/20 | 0.69 |
| ▸ | CACNA1B | Q00975 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CACNA1H | O95180 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilnidipine SCHEMBL25550 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL31398437 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL25551 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL30209784 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL3334757 | 1.00 | CACNA1C (1.00) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL28356318 | 0.99 | CACNA1C (0.98) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL29248832 | 0.99 | CACNA1C (0.98) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL27852253 | 0.97 | CACNA1C (0.95) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| Cilnidipine SCHEMBL29141421 | 0.95 | CACNA1C (0.90) | CACNA1CCACNA1BMEN1KMT2AADORA3 | |
| SCHEMBL10739961 | 0.94 | CACNA1B (0.94) | CACNA1CCACNA1BMEN1KMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741007-A2 | METHOD OF TREATING OR PREVENTING AN ADVERSE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING A HAEMORRHAGIC STROKE | CSL Behring AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250346646-A1 | COMPOUNDS USEFUL TO TREAT METABOLIC DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250304655-A1 | Expression System for Producing a Recombinant Haptoglobin (Hp) Beta Chain | CSL BEHRING AG (CH) | 2025-10-02 | — | — | US | disclosed |
| EP-2958562-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| US-20250049881-A1 | FORMULATIONS OF GUANYLATE CYCLSE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2025-02-13 | — | — | US | disclosed |
| US-20250026719-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2024-11-19 | — | — | US | disclosed |
| EP-4424697-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Bausch Health Ireland Limited (IE) | 2024-09-04 | — | — | EP | disclosed |
| EP-4090650-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) | 2022-11-23 | — | — | EP | disclosed |
| WO-2022234070-A1 | EXPRESSION SYSTEM FOR PRODUCING A RECOMBINANT HAPTOGLOBIN (HP) BETA CHAIN | CSL BEHRING AG (CH) | 2022-11-10 | — | — | WO | disclosed |
| CN-109642908-B | Compounds useful for treating metabolic disorders | 哈佛学院院长及董事 | 2022-08-16 | — | — | CN | disclosed |
| WO-2022162218-A1 | METHOD OF TREATING OR PREVENTING AN ADVERSE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING A HAEMORRHAGIC STROKE | CSL BEHRING AG (CH) | 2022-08-04 | — | — | WO | disclosed |
| US-20220211808-A1 | HAPTOGLOBIN FOR USE IN TREATING AN ADVERSE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING A HAEMORRHAGIC STROKE | UNIVERSITAET ZUERICH (CH) | 2022-07-07 | — | — | US | disclosed |
| US-11345748-B2 | Method of treating idiopathic pulmonary fibrosis and kidney fibrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-05-31 | — | — | US | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
| EP-3968988-A1 | HAPTOGLOBIN FOR USE IN TREATING AN ADVERSE SECONDARY NEUROLOGICAL OUTCOME FOLLOWING A HAEMORRHAGIC STROKE | Universität Zürich (CH) | 2022-03-23 | — | — | EP | disclosed |
| CN-114007639-A | Haptoglobin for the treatment of adverse secondary neurological consequences following hemorrhagic stroke | 苏黎世大学 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | CACNA1C 671/4885CACNA1F 1605/4885CACNA1D 1070/4885 |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CACNA1C 671/4885CACNA1F 1605/4885CACNA1D 1070/4885 |
| US-20250026719-A1 | NOVEL COMPOUNDS AS INHIBITORS OF PCSK9 | PCSK9, PCSK7, PCSK6 | CACNA1C 4774/4885CACNA1F 4723/4885CACNA1D 4739/4885 |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | CACNA1C 671/4885CACNA1F 1605/4885CACNA1D 1070/4885 |
| US-11345748-B2 | Method of treating idiopathic pulmonary fibrosis and kidney fibrosis | CNR2, FABP1, FABP4 | CACNA1C 2642/4885CACNA1F 2950/4885CACNA1D 2787/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | CACNA1C 671/4885CACNA1F 1605/4885CACNA1D 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.